Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2019 - 2026)

Zentalis Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $500000.0 for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 10.39% year-over-year to $500000.0 in Q1 2026; TTM through Mar 2026 was $500000.0, a 10.39% decrease from a year earlier, with the FY2025 full-year figure at $500000.0, down 41.11% from the prior year.
• Other Non-Current Liabilities was little changed at $500000.0 in Q1 2026 per ZNTL's latest filing, from $500000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $45.0 million in Q1 2022 and bottomed at $500000.0 in Q2 2023.
• The 5-year median for Other Non-Current Liabilities is $996000.0 (2024), against an average of $4.0 million.
• Across the five-year window, Other Non-Current Liabilities jumped 10168.95% in 2022 and sank 96.02% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $2.6 million in 2022, then tumbled by 32.06% to $1.8 million in 2023, then plunged by 52.3% to $849000.0 in 2024, then tumbled by 41.11% to $500000.0 in 2025, then changed by 0.0% to $500000.0 in 2026.
• Per Business Quant, the three latest ZNTL Other Non-Current Liabilities figures stand at $500000.0 (Q1 2026), $500000.0 (Q4 2025), and $500000.0 (Q3 2025).